ebola
viru
ebov
infect
secret
glycoprotein
sgp
found
larg
quantiti
serum
patient
infect
anim
model
thought
serv
decoy
antiebov
antibodi
use
vitro
model
incorpor
treatment
noninfect
human
macrophag
recombin
ebov
sgp
studi
sought
examin
impact
sgp
upon
key
macrophag
function
macrophag
polar
phagocyt
capac
activ
macrophag
found
unalt
sgp
treatment
howev
treatment
sgp
inhibit
macrophag
product
proinflammatori
cytokin
yield
antiinflammatori
cytokin
remain
intact
interestingli
migratori
abil
macrophag
also
diminish
sgp
potenti
due
decreas
express
vital
macrophag
integrin
thu
ebov
sgp
may
oper
diminish
function
contribut
noninfect
macrophag
increas
potenti
viral
dissemin
recent
devast
outbreak
zair
ebolaviru
ebov
western
africa
shown
inadequaci
world
healthcar
system
even
though
first
record
ebov
outbreak
much
pathogenesi
virion
remain
unclear
much
effort
focus
action
viral
protein
produc
within
infect
immun
macrophag
dendrit
cell
tissu
cell
much
left
discov
regard
interact
solubl
ebola
viru
protein
infiltr
noninfect
immun
cell
macrophag
within
order
mononegaviral
famili
filovirida
genu
ebolaviru
current
five
speci
viru
speci
includ
zair
sudan
reston
bundibugyo
forest
speci
infect
caus
diseas
human
except
reston
viru
zair
strain
common
known
outbreak
one
studi
laboratori
set
ebolaviru
virion
envelop
virion
neg
singlestrand
rna
genom
genom
encod
eight
differ
protein
includ
envelop
spike
glycoprotein
gp
glycoprotein
consist
two
subunit
g
g
g
subunit
mucinlik
domain
highli
glycosyl
usual
implic
attach
host
cell
glycoprotein
transmembran
portion
ctermin
end
cleav
tumor
necrosi
factoralpha
convert
enzym
tace
cleavag
creat
shed
glycoprotein
delta
peptid
portion
shed
glycoprotein
subject
sever
studi
howev
biolog
function
shed
glycoprotein
complet
defin
suggest
sequest
antibodi
spike
glycoprotein
help
virion
immun
evas
could
caus
product
proinflammatori
cytokin
glycoprotein
also
cleav
tace
cleavag
site
remain
intracellular
protein
lack
transmembran
domain
delta
peptid
secret
normal
secretori
pathway
protein
known
secret
glycoprotein
sgp
solubl
form
gp
shed
secret
measur
high
level
within
patient
blood
serum
macrophag
critic
import
sentinel
cell
detect
respond
threat
within
bodi
depend
upon
type
challeng
acquir
rel
phenotyp
better
equip
effici
respond
threat
macrophag
face
bacteri
viral
infect
assum
classic
phenotyp
associ
high
proinflammatori
etc
cytokin
product
high
phagocyt
capabl
macrophag
fight
helminth
infect
assum
phenotyp
associ
higher
product
antiinflammatori
cytokin
etc
effector
molecul
etc
cell
marker
etc
macrophag
dendrit
cell
dc
earli
target
ebov
pathogenesi
infect
cell
gain
access
blood
dissemin
viru
system
tissu
blood
vasculatur
viral
invas
endothelia
product
proinflammatori
cytokin
circul
infect
macrophag
dc
lead
develop
viral
hemorrhag
fever
characterist
ebov
infect
report
macrophag
monocyt
reduc
proinflammatori
cytokin
product
incub
ebov
sgp
inhibitori
effect
sgp
insuffici
counter
concomit
stimul
lipopolysaccharid
lp
furthermor
sgp
effect
upon
capac
activ
macrophag
phagocytos
antigen
howev
chemotaxi
activ
macrophag
significantli
diminish
sgp
like
associ
reduc
level
integrin
overal
ebov
sgp
may
major
role
pathogenesi
ebov
impair
activ
macrophag
human
monocyt
cell
atcc
cultur
complet
media
contain
rpmi
ge
healthcar
supplement
fb
heatinactiv
min
mm
gentamycin
cell
maintain
incub
co
humidifi
atmospher
monocyt
cell
differenti
macrophag
incub
nm
phorbol
pma
stimul
follow
rest
macrophag
polar
phenotyp
ngml
h
phenotyp
ngml
ngml
h
phenotyp
confirm
use
flow
cytometri
assess
characterist
cellular
marker
data
shown
monocyt
macrophag
treat
lp
sigma
pb
h
wash
follow
incub
low
high
concentr
sgp
recombin
ebov
sgp
lack
transmembran
domain
ibt
bioservic
pb
h
ebov
sgp
use
studi
creat
mammalian
cell
fulli
glycosyl
inhibit
format
dimer
trimer
could
occur
altern
test
sgp
impact
prior
stimul
macrophag
sgp
ad
cytokin
polar
h
cultur
wash
activ
addit
h
lp
assess
effect
sgp
upon
macrophag
time
activ
involv
stimul
popul
lp
sgp
lp
sgp
pb
h
complet
assay
h
cell
supernat
harvest
test
elisa
elisa
assay
perform
util
readysetgo
elisa
kit
thermofish
scientif
follow
manufactur
instruct
elisa
procedur
read
biotek
eon
micropl
spectrophotomet
biotek
instrument
inc
analyz
use
gen
softwar
version
follow
incub
polar
macrophag
lp
sgp
pb
combin
indic
adher
cell
collect
cultur
plate
via
trypsin
trypsinedta
stain
perform
use
standard
procedur
fix
formalin
humanspecif
ebiosci
util
flow
cytometri
perform
use
millipor
guava
cytomet
millipor
analyz
guavasoft
softwar
abil
phagocytos
foreign
particl
measur
util
fitc
labeledchicken
ovalbumin
peptid
ovafitc
fisher
polar
macrophag
treat
lp
pb
h
wash
treat
sgp
pb
addit
h
cell
wash
ovafitc
mgml
complet
unconjug
ovalbumin
protein
mgml
invivogen
pb
ad
min
h
h
incub
time
adher
cell
collect
treatment
trypsinedta
cell
wash
three
time
cold
pb
remov
bound
phagocytos
molecul
cell
fix
formalin
analyz
flow
cytometri
cell
gate
exclud
debri
chemotaxi
assay
previous
describ
brief
corn
transwel
plate
sigma
pore
size
use
macrophag
treat
lp
sgp
pb
indic
trypsin
count
macrophag
place
apic
chamber
complet
media
ngml
peprotech
ad
basal
chamber
well
pb
other
cell
incub
h
remain
macrophag
well
trypsin
count
use
hemocytomet
becton
dickinson
compani
measur
via
flow
cytometri
cell
gate
exclud
debri
cell
migrat
across
membran
event
per
flow
data
repres
percent
increas
chemotaxi
calcul
number
cell
migrat
basal
chamber
without
chemokinenumb
cell
migrat
basal
chamber
presenc
chemokin
mean
standard
deviat
express
data
assess
statist
signific
use
unpair
student
ttest
compar
two
group
pvalu
consid
signific
unless
otherwis
note
experi
perform
duplic
perform
minimum
three
time
observ
consist
trend
certainli
ebov
initi
infect
invad
tissu
macrophag
dendrit
cell
ultim
result
system
dissemin
entri
point
interestingli
viru
direct
synthesi
secret
modifi
glycoprotein
sgp
infect
cell
surround
tissu
blood
purpos
maneuv
may
deter
immun
reactiv
could
slow
replic
dissemin
process
rather
simpli
act
antiebov
antibodi
sink
like
case
earli
phase
diseas
prior
antibodi
synthesi
given
import
monocyt
macrophag
earli
innat
respons
viral
invad
first
sought
examin
effect
ebov
sgp
upon
activ
noninfect
monocyt
macrophag
order
test
vitro
human
monocyt
cell
line
differenti
macrophag
treatment
nm
pma
three
day
follow
fiveday
rest
use
sourc
cell
monocyt
macrophag
challeng
lp
h
way
activ
cell
trigger
cytokin
product
subsequ
cell
wash
pb
treat
either
low
high
dose
sgp
h
product
monocyt
statist
affect
either
dosag
sgp
fig
howev
product
macrophag
significantli
inhibit
presenc
sgp
fig
low
high
dose
sgp
seem
affect
activ
macrophag
equal
therefor
chose
use
low
dose
throughout
remaind
studi
result
suggest
sgp
may
direct
inhibitori
effect
noninfect
macrophag
differenti
macrophag
polar
phenotyp
treatment
test
whether
sgp
inhibit
polar
macrophag
macrophag
incub
sgp
simultan
h
wash
stimul
lp
induc
cytokin
product
ebov
sgp
present
polar
macrophag
signific
effect
cytokin
profil
characterist
macrophag
fig
product
proinflammatori
cytokin
high
macrophag
compar
rest
macrophag
signific
chang
cytokin
level
macrophag
polar
presenc
sgp
typic
macrophag
produc
low
level
antiinflammatori
cytokin
upon
stimul
lp
level
cytokin
affect
presenc
sgp
polar
fig
interestingli
basal
level
product
macrophag
significantli
greater
lpsstimul
cell
like
due
abil
lp
promot
macrophag
function
therebi
result
lower
product
stimul
cell
note
basal
product
sgpcultur
macrophag
decreas
rel
lpsstimul
cell
possibl
sgp
ligat
unknown
receptor
macrophag
result
activ
adaptor
protein
oper
reduc
basal
releas
howev
activ
sgptreat
macrophag
result
restor
level
lpsstimul
cell
test
whether
sgp
effect
upon
polar
macrophag
macrophag
treat
sgp
h
wash
subsequ
activ
lp
addit
h
macrophag
produc
low
level
proinflammatori
cytokin
high
level
compar
macrophag
fig
sgp
given
time
polar
cytokin
product
macrophag
unchang
fig
addit
signific
inhibit
basal
note
sgptreat
macrophag
evid
macrophag
given
cytokin
overal
find
indic
sgp
disturb
process
macrophag
polar
may
role
function
polar
macrophag
consid
whether
sgp
impact
noninfect
macrophag
function
sgp
solubl
viral
protein
would
like
encount
macrophag
within
bodi
either
previous
activ
undergo
activ
test
hypothesi
sgp
inhibit
function
polar
noninfect
macrophag
previous
activ
microbi
stimuli
lp
macrophag
cultur
h
follow
lp
pb
h
subsequ
cell
wash
pb
treat
sgp
pb
addit
h
therefor
total
incub
time
polar
activ
supernat
harvest
h
strikingli
sgp
abl
inhibit
product
proinflammatori
cytokin
affect
level
antiinflammatori
cytokin
macrophag
fig
sgp
alon
provok
cytokin
product
macrophag
perhap
treatment
polar
macrophag
lp
sgp
reduc
cellular
viabil
order
determin
experiment
approach
promot
cell
death
cell
macrophag
cultur
assess
express
cell
viabil
stain
flow
cytometri
viabil
greater
observ
group
lp
sgp
lp
sgp
test
supplementari
fig
therefor
sgp
abl
inhibit
product
proinflammatori
cytokin
previous
activ
polar
macrophag
sgp
restrain
polar
macrophag
produc
cytokin
given
simultan
lp
stimuli
test
possibl
macrophag
cultur
lp
sgp
h
interestingli
signific
differ
lp
sgp
lp
treat
macrophag
term
product
fig
result
suggest
ebov
sgp
select
inhibit
product
proinflammatori
cytokin
antiinflammatori
cytokin
activ
macrophag
furthermor
inhibitori
effect
could
supersed
stimulatori
effect
lp
one
import
effector
function
macrophag
capac
phagocytos
microbi
pathogen
macrophag
recogn
selfand
nonselfparticl
phagocytos
destruct
antigen
present
given
ebov
sgp
abl
interfer
proinflammatori
cytokin
product
previous
activ
macrophag
fig
b
may
act
suppress
earli
immun
respons
gener
profession
phagocyt
macrophag
aid
earli
respons
control
clear
bodi
microbi
invad
prior
assess
sgp
abil
impair
phagocyt
activ
macrophag
treat
pb
unconjug
complet
ova
protein
mgml
ovafitc
mgml
incub
min
h
h
determin
optimum
incub
time
assay
trypsin
cell
wash
time
cold
pb
stop
antigen
uptak
remov
particl
bound
cellular
surfac
assess
antigen
accumul
within
cell
shown
fig
period
intens
ova
accumul
increas
cultur
time
determin
optim
incub
time
test
capac
ebov
sgp
modul
phagocyt
capabl
macrophag
cell
activ
either
lp
pb
h
wash
treat
either
sgp
pb
addit
h
fig
percentag
cell
phagocytos
ovafitc
particl
statist
unremark
lp
group
group
activ
lp
treat
sgp
fig
suggest
phagocyt
abil
macrophag
pivot
macrophag
function
significantli
affect
presenc
ebov
sgp
interestingli
phagocyt
activ
macrophag
alter
ebov
sgp
proinflammatori
cytokin
product
inhibit
viral
protein
may
oper
promot
ebov
surviv
dissemin
impair
inflammationrel
event
associ
migrat
cytokin
product
noninfect
macrophag
therefor
test
chemotact
abil
activ
macrophag
treatment
sgp
previous
activ
macrophag
incub
sgp
h
wash
place
apic
chamber
chemotaxi
assay
chemokin
monocyt
chemoattract
pb
ad
basal
chamber
complet
media
macrophag
allow
migrat
basal
chamber
h
upon
harvest
live
cell
basal
chamber
count
assess
live
cell
well
flow
cytometri
fig
activ
macrophag
lp
pb
lp
sgp
show
signific
increas
percent
chemotaxi
compar
inactiv
macrophag
pb
pb
pb
sgp
percent
chemotaxi
activ
macrophag
treat
sgp
decreas
compar
activ
macrophag
incub
pb
result
suggest
lp
provok
migratori
function
macrophag
sgp
oper
impair
migrat
activ
macrophag
toward
macrophag
migrat
toward
compromis
presenc
ebov
sgp
interestingli
integrin
shown
critic
migrat
macrophag
dendrit
cell
toward
chemokin
therefor
ebov
sgp
may
alter
express
impact
migratori
capac
activ
macrophag
test
possibl
activ
macrophag
cultur
sgp
h
express
assess
flow
cytometri
inde
level
surfac
decreas
activ
macrophag
incub
sgp
sgp
addit
h
sgp
lp
group
ngml
ngml
ngml
sgp
given
h
cell
wash
lp
ad
h
supernat
cultur
harvest
total
incub
hour
product
measur
via
elisa
n
p
ns
indic
signific
fig
suggest
ebov
sgp
decreas
chemotact
abil
activ
macrophag
reduc
express
current
major
role
sgp
ebov
pathogenesi
yet
clearli
demonstr
previous
thought
primari
role
sgp
serv
pathogenesi
act
decoy
molecul
antibodi
product
studi
show
first
time
sgp
profound
inhibitori
effect
upon
activ
macrophag
may
condit
cell
suscept
infect
progeni
virion
ebov
sgp
inhibit
product
proinflammatori
cytokin
impair
chemotaxi
downregul
integrin
express
phagocytosi
activ
macrophag
unaffect
consist
recent
data
support
notion
ebov
util
apoptot
mimicri
phagocytosi
mechan
invad
macrophag
thu
find
suggest
sgp
produc
halt
activ
macrophag
antivir
activ
potenti
preserv
entri
site
virion
addit
activ
macrophag
infect
ebov
glycoprotein
viral
may
oper
overrid
sgpmediat
inhibit
restor
migrat
cytokin
product
result
system
dissemin
viru
viral
hemorrhag
fever
ebov
titer
shown
peak
plateau
day
postinfect
level
greater
titer
level
influenza
viru
infect
suggest
unusu
high
rate
viral
replic
like
accompani
larg
amount
pathogenassoci
molecular
pattern
includ
viral
nucleic
acid
respons
fig
macrophag
proinflammatori
cytokin
product
inhibit
ebov
sgp
given
activ
activ
monocyt
differenti
macrophag
pb
lp
sgp
group
macrophag
treat
h
c
ngml
b
ngml
ngml
subsequ
macrophag
stimul
pb
lp
sgp
addit
h
lp
sgp
group
ngml
b
ngml
ngml
given
h
cell
wash
lp
given
h
cell
wash
sgp
ad
h
cd
lp
sgp
group
lp
sgp
given
simultan
h
polar
step
supernat
cultur
harvest
product
measur
via
elisa
n
p
ns
indic
signific
monocyt
shown
emigr
bone
marrow
bloodstream
first
h
microbi
infect
howev
system
spread
viru
high
mortal
suggest
despit
rapid
mobil
innat
respons
ebov
abl
overwhelm
earli
host
respons
order
infect
carrier
cell
ie
macrophag
dc
purpos
dissemin
viru
site
initi
infect
hypothesi
put
forward
work
ebov
sgp
oper
inhibit
effector
activ
immun
cell
prior
infect
effort
assess
modul
dc
sgp
underway
unpublish
data
focu
monocyt
macrophag
rest
activ
monocyt
littl
impact
upon
viral
replic
given
limit
phagocyt
abil
cytokin
product
like
target
ebov
sgp
notion
support
inabl
sgp
alter
product
monocyt
fig
contrast
upon
differenti
monocyt
macrophag
use
pma
activ
lp
macrophag
produc
significantli
less
fig
therefor
sgp
impact
macrophag
differenti
monocyt
could
suggest
receptor
sgp
bind
express
differenti
macrophag
monocyt
work
proceed
identifi
sgp
receptor
well
signal
may
initi
macrophag
upon
incub
sgp
differenti
macrophag
undergo
polar
effector
cell
order
support
microbi
elimin
genet
program
configur
particular
group
pathogen
bacteriavirus
helminth
respect
virus
sever
acut
respiratori
syndrom
coronaviru
human
immunodefici
viru
human
cytomegaloviru
associ
promot
polar
support
success
viral
replic
thu
thought
ebov
may
similarli
promot
polar
secret
viral
protein
modul
process
use
vitro
model
ebov
sgp
demonstr
abil
affect
polar
macrophag
phenotyp
fig
would
seem
suggest
spread
ebov
benefit
correctli
polar
macrophag
macrophag
cultur
sgp
prior
activ
lp
strongli
suggest
receptor
viral
protein
express
upregul
cell
stimul
inde
product
affect
sgp
given
macrophag
activ
activ
product
also
affect
sgp
given
polar
macrophag
note
howev
sgp
given
polar
macrophag
product
significantli
decreas
could
possibl
due
activ
sgpmediat
activ
regulatori
adaptor
protein
interferon
regulatori
profound
inhibitori
effect
proinflammatori
cytokin
product
milder
inhibitori
effect
product
fact
sgp
interfer
product
given
polar
step
could
due
role
regulatori
protein
differenti
process
hematopoiet
stem
cell
previous
shown
target
viral
process
suppress
immun
respons
promot
viral
pathogenesi
therefor
possibl
presenc
sgp
promot
activ
suppress
proinflammatori
cytokin
impact
product
macrophag
possibl
pursu
futur
work
previou
studi
report
shed
ebov
glycoprotein
mitig
product
proinflammatori
cytokin
innat
immun
cell
author
state
secret
version
unabl
stimul
macrophag
studi
also
show
solubl
ebov
glycoprotein
shed
secret
spike
effect
macrophag
studi
ask
whether
nonactiv
macrophag
stimul
produc
cytokin
treat
ebov
secret
glycoprotein
essenti
ask
whether
sgp
stimul
macrophag
cytokin
product
thu
find
sgp
inhibit
product
proinflammatori
cytokin
previous
activ
macrophag
novel
fig
inhibitori
effect
sgp
upon
product
may
occur
either
genet
protein
secret
level
administ
mice
halflif
lp
h
like
much
shorter
vitro
given
macrophag
activ
lp
h
wash
remov
excess
lp
sgp
ad
suggest
sgp
compet
lp
bind
thought
shed
gp
ebov
sgp
must
affect
lpsinduc
signal
downstream
perhap
interven
inhibit
activ
reinstat
action
kinas
ikk
anoth
lpsinduc
pathway
may
influenc
sgp
mitogenactiv
protein
kinas
mapk
lp
bind
tolllik
receptor
induc
signal
recruit
phosphoryl
receptorassoci
kinas
turn
activ
mapk
subsequ
activ
lead
cytokin
product
two
protein
block
may
trigger
sgp
tollip
irakm
anoth
protein
suppressor
cytokin
could
also
induc
sgp
interfer
cytokin
product
addit
sinc
product
macrophag
unchang
presenc
sgp
highli
unlik
sgp
imped
proinflammatori
cytokin
product
block
protein
secretori
pathway
understand
sgp
affect
well
mapk
signal
pathway
lead
cytokin
product
underway
sgp
appear
capac
interfer
lpsmediat
signal
follow
activ
sgp
incap
alter
lp
signal
given
time
stimul
fig
possibl
sgp
much
shorter
halflif
lp
thu
cytokin
could
reduc
short
term
restor
time
cytokin
concentr
determin
endpoint
experi
examin
cytokin
product
h
address
issu
rapid
turnov
may
account
project
high
level
sgp
tissu
blood
infect
anim
ebov
gp
lp
also
suggest
compet
receptor
possibl
attach
factor
viru
express
macrophag
whether
secret
truncat
version
gp
may
also
bind
unknown
studi
sgp
appear
impact
upon
cellular
function
cell
activ
suggest
receptor
may
constitut
express
interestingli
relat
studi
natur
killer
nk
cell
lack
treatment
sgp
shown
inhibit
nk
effector
function
indic
sgp
may
least
altern
receptor
exist
activ
macrophag
nk
cell
unpublish
data
macrophag
wide
known
abil
phagocytos
particl
clean
cellular
debri
tissu
phagocyt
action
increas
macrophag
assum
phenotyp
rel
lower
phenotyp
solubl
antigen
ovalbumin
shown
phagocytos
dc
via
ctype
lectin
mannos
receptor
ctype
lectin
also
implic
possibl
attach
factor
ebov
entri
host
cell
interestingli
phagocytosi
ovalbumin
activ
macrophag
affect
treatment
sgp
fig
propos
hypothesi
correct
sgp
would
interfer
abil
macrophag
uptak
viru
ctype
lectin
thu
ctype
lectin
may
import
ebov
ligand
cell
entri
migratori
abil
macrophag
essenti
function
antigenpres
cell
ebov
sgp
exhibit
abil
diminish
capac
macrophag
migrat
respons
fig
interestingli
integrin
wide
accept
marker
macrophag
phenotyp
also
shown
necessari
chemotact
abil
activ
macrophag
assess
activ
macrophag
incub
sgp
demonstr
reduc
express
cellular
marker
compar
control
fig
conclus
result
suggest
novel
mechan
wherebi
ebov
sgp
shut
antivir
immun
mediat
activ
macrophag
creat
pool
suscept
cell
prime
infect
inde
ebov
sgp
inhibit
proinflammatori
cytokin
product
chemotaxi
preserv
cellular
abil
take
antigen
therefor
sgp
may
play
major
role
ebov
pathogenesi
two
way
first
impair
activ
macrophag
viru
rapidli
produc
progeni
virion
spread
part
bodi
second
paralyz
macrophag
serv
pool
suscept
host
cell
infect
inform
may
import
consider
devis
therapi
given
unusu
high
replic
rate
viru
copiou
product
solubl
viral
protein
sgp
may
diminish
efficaci
host
immun
